Bangalore, India:  DA Prasanna, Founder and Chairman of EA, is pleased toannounce the appointment of Lalit Kanta Mahapatra as Chief Financial Officer (CFO) of EA.

Lalit will be based in Bangalore and will be responsible for controllership, financial management and financial integration of business across services and geographies. Reporting to the Chairman of the Board, he will manage shareholders expectations , oversee corporate governance and lead the M&A activities of the company.

Prior to joining EA, Lalit worked with Schneider Electric Company as Head of Finance of the Global Technology Centre and the project contracting business. He was part of their global acquisition team and was instrumental in acquiring companies in India and Europe.

Lalit has over 15 years experience with companies like Siemens Information Processing Services Limited, Pacific Internet and Price Water House Cooper. His areas of expertise include strategic planning, fund management & harmonizing accounting practices to US GAAP, global IFRS standard and Indian GAAP. He is also a SAP champion in Finance module.

Speaking on the appointment, DA Prasanna said, “Lalit brings a wealth of experience to realize our aspiration of profitable growth and leadership in clinical research services.”

On his appointment, Lalit Mahapatra said, “My experience has garnered me exposure in both European and Asian markets. I am excited to be a part of EA that has grown manifold in a short span of time and has been committed to global compliance. I believe in this company and look forward to contributing to its future.”

Notes to the editor: (www.ecronacunova.com) EA is an expert CRO with more than 20 years of track record, providing services for Phase I-IV clinical research, including clinical trial management, clinical data management, PK/PD services and central lab with its research centers in Europe and India. As regional experts EA operates each region as a priority market with a European HQ at Frankfurt (Germany) and an Asian HQ at Bangalore (India). EA covers 15 Western & Eastern European countries including Russia & Ukraine. Supplemented by alliance partners, EA offers a well-directed multi-continental geographical spread. Apart from deep competence in conventional clinical research areas like oncology, cardiovascular disease, pulmonology, metabolic disorders, ophthalmology, etc, EA provides unique expertise in diagnostic imaging and stem cell therapy trials. High service quality, wide therapeutic expertise and continuously expanding global reach are central to EA’s long lasting commitment. EA is committed to deliver speed-to-market cost effectively with no compromise on quality.